Veeva’s vice president of global business consulting discusses recent trends in HCP access and how the pharma industry is reacting.
HCP Access Drops but Connected Field Engagement Breaks Through: Q&A with Dan Rizzo
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours